Skip to main content
Figure 2 | Cancer Cell International

Figure 2

From: Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies

Figure 2

Mapping of the binding domain of adecatumumab to exon 5 of human EpCAM. a Comparison of exon 5 sequences from human, cynomolgus and murine EpCAM. The lines mark sequences of highest diversity between human and cynomolgus EpCAM. b Human/cynomolgus monkey chimera expressed on 293 cells for mapping the binding site for adeactumumab. The results of the FACS-based binding assay are shown on the right. c FACS histograms showing the binding of adecatumumab to 293 cells expressing the EpCAM constructs shown in b. The bold line shows binding of detection antibodies in the presence of adecatumumab, the faint line binding in the absence of the mAb. MFI, mean fluorescence intensity.

Back to article page
\